Get started

Swingtrading

PFOCUS is Focusing on 2008's Multi-Year Long Resistance BreakoutNSE:PFOCUS ............................................................................................................................................. ............................................................................................................................................. Over Last 4 Years ... From Year 2020 to 2024 Promoter Holdings Have Been Increased by +34.93% ...... ............................................................................................................................................. ............................................................................................................................................. Customers PFL caters to players across the entire media industry value chain and the product life cycle of media content. Its major clients include top Hollywood and Indian studios and media companies across the globe: Studios – Warner Bros., Disney, Netflix, etc. Broadcast networks – Bloomberg, Disney, Star, etc. Others – ICC, BCCI, Amazon, etc. ............................................................................................................................................. ............................................................................................................................................. Focus In Creative Services, it aims to expand its global footprint and diversify the business across content formats. It also expects growth in cross-selling through bundled VFX, etc. In Tech/Tech-Enabled Services it aims to sign more strategic deals and increase revenue from existing clients by offering new modules and analytics. Working on top Hollywood projects One of them is Matrix 4
NSE:PFOCUSLong
by iism-ExpertTrading
ALPHAGEO Strong Fundamental Turn-Around Story NSE:ALPHAGEO ...................................................................................................................... ...................................................................................................................... Incorporated in 1987, Alphageo Ltd provides Geophysical Seismic Data Acquisition, Processing and Interpretation Services for exploration of hydrocarbons and minerals ...................................................................................................................... ...................................................................................................................... Company is almost debt free. Stock is trading at 1.03 times its book value. Company is expected to give good quarter. Company has been maintaining a healthy dividend payout of 473%. ...................................................................................................................... ...................................................................................................................... Due to effect of monsoon in several parts of India, only 4 seismic crews worked in the month of October 2019, with an addition of another 5 crews in the month of November 2019. The NSP Project on Sedimentary Basins of of Ganga-Punjab Area with Oil and Natural Gas Corporation Ltd. has been completed in the first week of January 2020. • The field acquisition stage of the Project of Geophysical Mapping Survey for mineral exploration with Geological Survey of India has been completed. The processing, interpretation and submission of deliverables is in progress. • The Project for MECL is completed during the quarter ended 31st December, 2019 • No new orders were received during the quarter under review. • Order on hand as on 31st December, 2019: INR 160 Cr (inclusive of taxes)
NSE:ALPHAGEOLong
by iism-ExpertTrading
MMTC Non Profitable PSU showing MULTI-YEAR BreakoutNSE:MMTC ...................................................................................................................... ...................................................................................................................... As A Research Analyst ... It is Not an Good Practice to Suggest anyone to invest in Non-Profitable and Loss Making Company.... Every Fundamental Numbers are Either Negative or Not-Satisfying ....... but if we See in Terms of Technical Analysis.... MMTC is Showing Long-Multi-Year Breakout.... so Going with Defined Risk... keeping an Decent Percentage of SL ... ...................................................................................................................... ...................................................................................................................... MMTC, a public sector undertaking, was incorporated in 1963, to facilitate foreign trade in India and canalize the export and import of essential minerals and metals. It is under the administrative control of the Ministry of Commerce & Industry, and Government of India and is engaged in trading across minerals, metals, precious metals, agro products, fertilizers & chemicals and coal & hydrocarbons.
NSE:MMTCLong
by iism-ExpertTrading
ADANI WILMAR Showing Breakage in Volume & Structure,NSE:AWL ....................................................................... Not a Adani Lover.... But Some Bussinesses are Considered as White Collar.... Specially when you are aware of the original Product of the company. ............................................................................................................................................. ............................................................................................................................................. Strong recovery in Profitability, after subdued profits in H1 of last year. ➢ Trailing 9-Month EBITDA at INR 1,471 Crore. ➢ Profitability was volatile in FY24 due to hedge dis-alignment. However, profitability is improving over the longer-term. ............................................................................................................................................. ............................................................................................................................................. ▪ Q1 volume growth of 12% YoY ▪ Steady growth in staple packaged foods. Edible oils grew by 12% YoY and Foods & FMCG grew by 42% YoY ▪ In Industry essential segment, both Oleo and Castor business grew in double digits, though overall volume impacted due to oil meal business ▪ Q1 revenue at INR 14,169 crores ▪ Revenue grew by 10% YoY in-line with volume growth as lapping of disinflationary impact of edible oil prices on revenue is complete ▪ Highest-ever EBITDA in Q1‘25 at INR 619 crores ▪ Edible oil business profitability has improved on back of stable edible oil prices ▪ Demand Environment (branded oil and foods) ▪ Demand environment stays steady in packaged staple foods on back of ongoing shift towards branded products ▪ Company stays focused on gaining market share, particularly in under-indexed markets & categories ▪ Incorporating local nuances to enhance regional engagement through customized campaigns, specialized packaging, localized pricing strategies, targeted schemes ▪ ESG Update ▪ Adani Wilmar has been included in FTSE4Good Index Series ▪ Company is committed to improve its processes for ESG performance, enhance disclosures and participate in key ESG ratings ............................................................................................................................................. ............................................................................................................................................. Key Takeaways: Q1’25 ▪ Overall volumes grew by 12% YoY in Q1’25 ▪ Edible Oil volumes surpasses 1 Million MT in Q1’25 ▪ Food & FMCG crossed quarterly revenue of ~INR 1,500 Crores in Q1’25 ▪ Edible Oil: ▪ Edible Oil volumes grew by 12% YoY in Q1’25 ▪ Both Sunflower oil and Mustard oil grew double digit during the quarter. ▪ Food & FMCG: ❑ Food & FMCG volumes grew by 42% YoY (Ex-G2G business, Food volumes grew by 19% YoY) ❑ The revenue from branded products in the domestic market has been growing consistently YoY at over 30% for the past eleven quarters. ▪ Distribution: ❑ Company’s direct reach grew by 18% YoY to reach 7.4 Lac Outlets at the end of Q1’25 ❑ Rural towns coverage grew by 40% YoY to 30,000+ towns at the of June 2024 ▪ Channel Growth: ❑ Alternate channel grew by 19% YoY in Q1’25 (in volume terms) ❑ Branded exports grew by 36% YoY in Q1’25 (in volume terms) ❑ HoReCa business grew by 91% YoY (in volume terms), with quarterly revenues crossing ~INR 150 Crore in Q1’25 ▪ ESG: ❑ Inclusion of AWL in FTSE4Good Index Series
NSE:AWLLong
by iism-ExpertTrading
AVTNPL Showing Good MomentumNSE:AVTNPL ............................................................................................................................................................................................................................................ Products The main products of the Co. are - Marigold Extracts for Eye Care, Food Coloring & Poultry Pigmentation; Spice oleoresin and Oils for Food Coloring and Flavoring; Value added Teas - Decaffeinated Teas and Instant Teas; Animal Nutrition Products; and Rosemary extract. ............................................................................................................................................................................................................................................ Subsidiaries The Co. has 2 wholly owned subsidiaries, namely AVT Natural Europe Ltd. & AVT Natural S.A. De C.v., Mexico. AVT Natural Europe Ltd. is the marketing arm of the Company for decaffeinated tea and instant tea. AVT Natural SA DE C.V, Mexico has been established with an aim to capture the market for the Animal Nutritional products in the South American market and other markets. ............................................................................................................................................................................................................................................
NSE:AVTNPLLong
by iism-ExpertTrading
IOLCP Showing Change in Structure can go towards 52 Week HighNSE:IOLCP ...................................................................................................................... ...................................................................................................................... The Company’s turnover increased to ₹ 2,133 crore in FY24 from ₹ 983 crore in FY18 at a CAGR of 13.77% ...................................................................................................................... ...................................................................................................................... The share of regulated market sale has increased to ₹ 300 crore in FY24 from ₹100 crore in FY18 ...................................................................................................................... ...................................................................................................................... Increased contribution of non-Ibuprofen drugs from ₹35 crore in FY18 to ₹431 crore in FY24, showing a steady upward trend over the years ...................................................................................................................... ...................................................................................................................... Added more than 10 products since 2017 in APIs and chemical segments. The Company has recently commenced a new plant of Acetic Anhydride ...................................................................................................................... ...................................................................................................................... • The Indian API market is expected to grow at a CAGR of 13.7% over the four years. • India hosts 500 API manufacturers, contributing approximately 8% to the global API Industry. • As the largest supplier of generic medicines, India manufactures around 60,000 different generic brands across 60 therapeutic categories. • In FY24 India saw a 4.12% increase in the total imports of bulk drugs and intermediates, amounting to ₹ 37,721.88 crore, compared to ₹ 36,229.15 crore in FY23. • Indian medicines are preferred worldwide due to their combination of low price and high quality, earning India the title of "pharmacy of the world." ...................................................................................................................... ...................................................................................................................... Positive factors • Strongly improving operating performance, resulting in growth of more than 15% in total operating income and sustained EBIDTA margin of more than 20%, on a sustained. • Diversifying product portfolio and reducing dependency on its main product Ibuprofen and ethyl acetate to below 65% in the overall revenue. • Improving total debt to gross cash accruals (TD/GCA) and TD to profit before interest, lease rentals, depreciation, and taxation (TD/PBILDT) to below unity. ...................................................................................................................... ...................................................................................................................... Established market position and diversified product offering The company was incorporated, 1986 with the commencement of business in chemical segment. In 2000, the company started production of Ibuprofen. IOLCPL is one of the largest manufacturers of Ibuprofen with significant global share and the company is backward integrated for manufacturing Ibuprofen. IOLCPL has a market presence across more than 50 countries with sales contribution from exports forming around 28% of total sales in FY24 (PY: 29%). The company’s overseas customers are spread across Switzerland, Bangladesh, Spain, Indonesia, Hungary, United Kingdom, Nepal, China, Turkey and Japan, among others. The company is one of the largest manufacturers of Ibuprofen (capacity of 12000 MTPA) and has the second largest manufacturing capacity (12000MTPA) for Iso Butyl Benzene (key raw material for Ibuprofen)
NSE:IOLCPLong
by iism-ExpertTrading
ASX 200 mimics Wall Street's 'risk-on' rally into Jackson HoleOverbought indicators are of little use when markets are obsessed with rate cuts ahead of a key fed speech. Jerome Powell will speak at the Jackson hole symposium and Friday, and expectations for a dovish show are high. And that's helped Wall Street indices extend gains and the allowed the ASX 200 to tag along for the ride. But if this turns out to be a classic 'buy the rumour, sell the fact' tale, traders may need to factor in some of the overbought clues on the daily chart.
ASX24:AP1!Short
by CityIndex
USD/JPY: Seeking dips above 144USD bears are getting quite excited at the prospects of a dovish speech from Jerome Powell on Friday. Perhaps a bit too excited. Market pricing has been quite dovish for some time now, so he will really have to crank up the dovish music on Friday to justify the latest surge of USD selling. USD/JPY fell over -12.5% from the July high to August low, yet formed a higher low above the Dec/Jan lows. We suspect a deeper retracement against that initial drop could be due. However, momentum is trying to turn lower on the 4-hour chart. Out bias is bullish while prices remain above 144, and will seek dips towards that level. A false break of Monday's low could work nicely (assuming prices pull back that far), in anticipation of a move back towards 150.
Long
by CityIndex
1
RUPA indicating is No More an Ordinary Underwear BrandNSE:RUPA Commenting on the financial performance Mr. Vikash Agarwal - Whole Time Director, said, “We are pleased to report a stable performance in Q1 FY25, though the industry continues to witness resistance to any price increase. We demonstrated steady improvements across key financial metrics. This quarter, we witnessed 8% rise in revenue, primarily driven by strong sales in our core product line. Our volume growth for the quarter reached 9%, supported by strong sales in the economy and athleisure segments. Our EBITDA saw a year-on-year increase of 59%, totaling Rs. 18.0 crores for the quarter, showcasing our commitment to cost management and operational efficiency. Operating margins also improved by 280 basis points compared to the same period last year. Furthermore, our net profit experienced substantial growth of 149%, reaching Rs. 10.5 crores for the quarter. This underscores the effectiveness of our financial strategies and the resilience of our business model. Net profit margins improved by 280 basis points during the quarter. Notably, our exports have shown progress, with a healthy 32% year-on-year growth, reaching Rs. 8 crores. This reflects our steady penetration into international markets. Revenue contribution from Modern Trade remains robust at 8% in Q1 FY25. The pilot project “Pragati’, which was launched last quarter, has received encouraging feedback from our distributors. We expect healthy expansion of the project going forward. Our cash flow from operations remains strong, generating Rs. 44 crores in Q1 FY25. We have made significant progress in reducing our debt, achieving a net debt-free status as at end of Q1 FY25. Our branding and advertising strategies accounted for 9% of revenues in Q1 FY25. Looking ahead, we are confident in achieving new business milestones and delivering innovative products to our diverse customer segments. Our customer-first approach will help us strengthen our position as an industry leader and contribute to our sustainable business model
NSE:RUPALong
by iism-ExpertTrading